About us
Enara Bio™ (formerly known as Ervaxx) is a science-led company targeting the T-cell/cancer cell interface (the “immune synapse”) to develop new targeted cancer immunotherapies designed to treat a broad patient population. We were founded as Ervaxx Ltd in late 2016 with an initial focus on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-related DNA sequences.
Our name Enara Bio™ is derived from an Arabic word meaning illumination, enlightenment and bringing light into the darkness.
We are exploring the hidden depths of cancer and T-cell biology to discover and characterize unconventional immunotherapy targets, such as MR1-presented ligands and Dark Antigens™, which arise from the altered cellular processes in cancer cells.
Enara Bio is backed by leading life science investors, including RA Capital, Samsara Biocapital and SV Health Investors. We collaborate with a number of world class academic institutions including the Francis Crick Institute, Cardiff University, Johns Hopkins School of Medicine and the University of Oxford, to help drive our differentiated science.
